Apolipoprotein A-IV, a putative satiety/antiatherogenic factor, rises after gastric bypass.
Apolipoprotein A-IV, a putative satiety/antiatherogenic factor, rises after gastric bypass.
复制标题
DOI：
10.1038/oby.2008.428
复制
发表时间：
2009-01
期刊：
影响因子：
6.9
通讯作者：
Lynch, Christopher J.
中科院分区：
文献类型：
--
作者：
Culnan, Derek M.;Cooney, Robert N.;Stanley, Bruce;Lynch, Christopher J.
Roux-en-Y胃旁路手术(RYGBP)可以改善饱腹感和肥胖相关的并发症。这些改进背后的机制(S)尚不清楚，但可能部分通过发现蛋白质组学揭示。因此，在RYGBP期间和第二次手术后约17个月，从12名受试者(平均BMI和GT；45)采集空腹血浆。服用RYGBP后，体重、肥胖相关的并发症和药物使用都减少了。使用等压同位素编码的亲和标签(4plex ITRAQ)对7个样品的子集进行基于质谱学的蛋白质组学分析。最初的蛋白质组学分析(n=7)对数百种血浆蛋白进行了量化和鉴定。人工检查数据显示，RYGBP后载脂蛋白A-IV(apo A-IV，基因代号：apoA4)增加了2.6±0.5倍，这是一种主要在旁路小肠和肝脏合成的46 kDa糖蛋白。载脂蛋白A-IV的变化明显大于其他载脂蛋白。对完整的纵向样本集(n=12)的免疫印迹分析表明，载脂蛋白A-IV的增加更高(8.3±0.2倍)。因此，与蛋白质印迹法相比，iTRAQ可能低估了载脂蛋白A-IV蛋白浓度的变化。载脂蛋白A-IV抑制胃排空，是一种饱腹感因子，其合成和分泌通过摄入膳食脂肪而增加。它还具有抗炎和抗动脉粥样硬化的特性。基于这些功能，我们推测载脂蛋白A-IV的变化可能有助于减轻体重以及改善RYGBP后的炎症和心血管疾病。此外，这些发现提供了证据，证实了在基于发现的研究中使用iTRAQ蛋白质组学来研究RYGBP治疗后肥胖相关医学合并症的改善。
Roux-en-Y gastric bypass surgery (RYGBP) leads to improvements in satiety and obesity-related co-morbidities. The mechanism(s) underlying these improvements are not known but may be revealed in part by discovery proteomics. Therefore, fasting plasma was collected from twelve subjects (mean BMI > 45 ) during RYGBP and a second procedure ~17 months later. Body weight, obesity-related co-morbidities and medication use were decreased following RYGBP. Mass spectrometry based proteomic analysis was performed on a subset of seven samples using isobaric isotope coded affinity tags (4 plex iTRAQ). Initial proteomic analysis (n=7) quantified and identified hundreds of plasma proteins. Manual inspection of the data revealed a 2.6 ± 0.5 fold increase in apolipoprotein A-IV (apo A-IV, Gene designation: APOA4), a ~46-kDa glycoprotein synthesized mainly in the bypassed small bowel and liver following RYGBP. The change in apoA-IV was significantly greater than other apolipoproteins. Immunoblot analysis of the full longitudinal sample set (n=12) indicated even higher increases (8.3 ± 0.2 fold) in apo A-IV. Thus iTRAQ may underestimate the changes in protein concentrations compared to Western blotting of apo A-IV. Apo A-IV inhibits gastric emptying and serves as a satiety factor whose synthesis and secretion are increased by the ingestion of dietary fat. It also possesses anti-inflammatory and anti-atherogenic properties. Based on these functions, we speculate changes in apo A-IV may contribute to weight loss as well as the improvements in inflammation and cardiovascular disease after RYGBP. In addition, the findings provide evidence validating the use of iTRAQ proteomics in discovery-based studies of post-RYGBP improvements in obesity-related medical co-morbidities.
登录
查看更多内容
影响因子：
2.9
作者：
FUJIMOTO, K;MACHIDORI, H;TSO, P
通讯作者：
TSO, P
影响因子：
16.2
作者：
Laferrere, Blandine;Heshka, Stanley;Olivan, Blanca
通讯作者：
Olivan, Blanca
DOI：
10.1016/0006-291x(87)90453-0
发表时间：
1987-01-15
影响因子：
3.1
作者：
PESSAH, M;SALVAT, C;INFANTE, R
通讯作者：
INFANTE, R
影响因子：
7.7
作者：
BARAKAT, HA;CARPENTER, JW;MARKS, R
通讯作者：
MARKS, R
影响因子：
3.5
作者：
Baralle, M;Vergnes, L;Ochoa, A
通讯作者：
Ochoa, A